Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Chief Legal Officer | October 02, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date October 02, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,110 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Exercise / conversion · Acquired 5,786 · Balance 14,896 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Row 2 · 2026-10-02 · Sale · Disposed 5,786 · Balance 9,110 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2034-02-12 | Direct | 111,251 |
Reported balance
After 2026-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-02 · Exercise / conversion · Disposed 5,786 · Balance 111,251 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.84 and the highest price at which shares were sold was $23.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2024 Filed Jul 30, 2024 23:06 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000105 · wk-form4_1722380764.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,760 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,546 Underlying: Common Stock · 5,760 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 801 | $21.57 | $17,277.33 |
DisclosureSEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,838 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $21.31 and the highest price at which shares were sold was $22.05. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 4,959 | $20.68 | $102,559.56 |
DisclosureSEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,639 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $20.24 and the highest price at which shares were sold was $21.13. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 01, 2024 Filed Jul 1, 2024 22:35 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 5,760 | $1.86 | $10,713.60 |
DisclosureSEC source: 0001549595-24-000090 · wk-form4_1719873314.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:39 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,864 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,306 Underlying: Common Stock · 1,864 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:39 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,864 | $17.02 | $31,721.18 |
DisclosureSEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,838 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.07. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:39 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,864 | $1.86 | $3,467.04 |
DisclosureSEC source: 0001549595-24-000081 · wk-form4_1718318368.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 23:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,170 Underlying: Common Stock · 1,900 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 23:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,900 | $17.01 | $32,319.00 |
DisclosureSEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,838 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 23:30 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,900 | $1.86 | $3,534.00 |
DisclosureSEC source: 0001549595-24-000079 · wk-form4_1718235042.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 22:01 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,070 Underlying: Common Stock · 400 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 22:01 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 400 | $17.00 | $6,801.00 |
DisclosureSEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,838 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.01. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 05, 2024 Filed Jun 5, 2024 22:01 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 400 | $1.86 | $744.00 |
DisclosureSEC source: 0001549595-24-000077 · wk-form4_1717624854.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,596 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,470 Underlying: Common Stock · 1,596 shares Expires 2029-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · derivative.exercise_date: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,596 | $17.01 | $27,152.91 |
DisclosureSEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,838 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $17.00 and the highest price at which shares were sold was $17.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 03, 2024 Filed Jun 3, 2024 22:36 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,596 | $1.86 | $2,968.56 |
DisclosureSEC source: 0001549595-24-000075 · wk-form4_1717454168.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,469 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,513 | $12.04 | $18,219.85 |
DisclosureSEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,838 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.9050 and the highest price at which shares were sold was $12.2000. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed Apr 30, 2024 22:33 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000053 · wk-form4_1714516375.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 12:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000019 · wk-form4_1707999786.xml · derivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 12:23 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001549595-24-000019 · wk-form4_1707999786.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:52 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:52 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,393 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:52 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,760 | $7.99 | $14,062.75 |
DisclosureSEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,427 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:52 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2024 Filed Jan 30, 2024 23:52 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-24-000007 · wk-form4_1706658755.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,232 | $5.20 | $6,403.20 |
DisclosureSEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,263 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $5.04 and the highest price at which shares were sold was $5.28. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,317 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:40 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001549595-23-000059 · wk-form4_1698871242.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 27 shares of Common Stock acquired by the Reporting Person on August 15, 2023, pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 20:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 1,420 | $9.65 | $13,709.67 |
DisclosureSEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,544 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.61 and the highest price at which shares were sold was $9.82. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043979 · doc4.xml · derivative · entry 5 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043979 · doc4.xml · derivative · entry 4 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,241 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2023 Filed Aug 1, 2023 20:27 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043979 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2023 Filed May 2, 2023 20:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 682 | $9.88 | $6,735.64 |
DisclosureSEC source: 0001209191-23-026519 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,040 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. F1 · balance_after: Includes 1,537 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| April 30, 2023 Filed May 2, 2023 20:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026519 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,165 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| April 30, 2023 Filed May 2, 2023 20:32 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026519 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,537 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantRestricted Stock Units · Derivative | 24,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-009709 · doc4.xml · derivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on April 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. F4 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:11 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantEmployee Stock Option (right to buy) · Derivative | 88,900 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0001209191-23-009709 · doc4.xml · derivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,900 Underlying: Common Stock · 88,900 shares Expires 2033-02-13 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning March 14, 2023 until the option is fully vested on February 14, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionRestricted Stock Units · Derivative | 1,924 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005906 · doc4.xml · derivative · entry 3 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,089 Underlying: Common Stock · 1,924 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: RSUs do not expire; they either vest or are canceled prior to the vest date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 848 | $11.78 | $9,989.10 |
DisclosureSEC source: 0001209191-23-005906 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,261 F1 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $11.60 and the highest price at which shares were sold was $12.00. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:16 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | Exercise / conversionCommon Stock | 1,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005906 · doc4.xml · nonDerivative · entry 1 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2022 Filed Nov 1, 2022 23:34 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | SaleCommon Stock | 699 | $12.88 | $9,003.47 |
DisclosureSEC source: 0001209191-22-055143 · doc4.xml · nonDerivative · entry 2 Ring Christine · CIK 0001817199 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,185 F2 · kind: The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $12.76 and the highest price at which shares were sold was $12.99. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.